These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 18824559)
1. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559 [TBL] [Abstract][Full Text] [Related]
2. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946 [TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335 [TBL] [Abstract][Full Text] [Related]
4. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159 [TBL] [Abstract][Full Text] [Related]
5. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500 [TBL] [Abstract][Full Text] [Related]
6. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells. Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360 [TBL] [Abstract][Full Text] [Related]
8. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698 [TBL] [Abstract][Full Text] [Related]
9. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation. Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830 [TBL] [Abstract][Full Text] [Related]
10. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro]. Zhang QY; Zhao WH; Kang XM Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003 [TBL] [Abstract][Full Text] [Related]
11. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780 [TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758 [TBL] [Abstract][Full Text] [Related]
13. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells]. Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274 [TBL] [Abstract][Full Text] [Related]
14. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
15. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
16. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen. Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819 [TBL] [Abstract][Full Text] [Related]
17. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413 [TBL] [Abstract][Full Text] [Related]
18. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049 [TBL] [Abstract][Full Text] [Related]
19. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Stoica GE; Franke TF; Wellstein A; Czubayko F; List HJ; Reiter R; Morgan E; Martin MB; Stoica A Mol Endocrinol; 2003 May; 17(5):818-30. PubMed ID: 12554767 [TBL] [Abstract][Full Text] [Related]
20. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]